Family HOPE Study (Hereditary Lynch Syndrome Opportunities for Participation &Amp; Engagement)

Status: Recruiting
Location: See location...
Intervention Type: Other, Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This clinical trial tests whether provider-mediated communication of genetic testing results to at-risk relatives of cancer patients can help improve genetic counseling and testing rates. Approximately 15% of people with cancer have an inherited form of cancer due to changes in a gene that they have inherited from one of their parents. These changes increase a person's risk for developing cancer. Most people who have an inherited harmful change in a cancer risk gene don't know that they have it and are therefore not able to get the health care that they need. The primary reason for this problem has been a lack of genetic counseling and testing for cancer patients and patients with a strong family history of cancer. Another reason for this lack of awareness is that, when cancer runs in a family, the patient who carries the gene change usually has to communicate the genetic risk information to their family members. When this process doesn't work well, family members may not know that they need to get genetic testing and then may not get potentially life-saving care. Provider-mediated contact to discuss genetic test results may help improve rates of genetic testing among at-risk relatives of patients with a family cancer syndrome.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• PATIENTS: Enrolled in City of Hope (COH) institutional review board (IRB) 07047 or have been seen by COH Genetics for genetic testing

• PATIENTS: Have an pathogenic/ likely pathogenic germline variant

• PATIENTS: Fluent in English

• PATIENTS: Age \>= 18 years

• PATIENTS: Willing to provide contact information for eligible first-degree relatives

• PATIENTS: \>= 2 first-degree relatives that are eligible for genetic testing and reside in the United States of America

• FIRST-DEGREE RELATIVES: Proband is a COH patient and has consented to this study

• FIRST-DEGREE RELATIVES: First-degree relative of proband

• FIRST-DEGREE RELATIVES: Resides within the United States

• FIRST-DEGREE RELATIVES: Has not undergone genetic testing for the known familial variant

• FIRST-DEGREE RELATIVES: Are fluent in English

• FIRST-DEGREE RELATIVES: Age \>= 18 years

Locations
United States
California
City of Hope Medical Center
RECRUITING
Duarte
Time Frame
Start Date: 2023-02-14
Estimated Completion Date: 2025-12-14
Participants
Target number of participants: 240
Treatments
Active_comparator: Arm I (usual care)
Patients receive a family letter and their genomic test report to share with at-risk first degree relatives on study.
Experimental: Arm II (provider-mediated contact)
Patients receive a family letter and their genomic test report to share with at-risk first degree relatives and relatives also receive provider-mediated contact to discuss genetic results on study.
Related Therapeutic Areas
Sponsors
Leads: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov